Welcome to our dedicated page for Cirtran SEC filings (Ticker: CIRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CirTran Corporation (CIRX) SEC filings, including registration statements, current reports, and notifications related to its reporting obligations. CirTran identifies itself as a Nevada-incorporated, smaller reporting company, and its common stock trades on the OTCID Market under the symbol CIRX.
Among the key documents are the company’s Form S-1 and Form S-1/A registration statements, which describe the resale of shares of common stock by YA II PN, Ltd. under a Standby Equity Purchase Agreement. These filings explain that CirTran may, at its discretion, issue and sell shares of common stock to YA up to a stated aggregate amount, subject to ownership limits and other conditions, and that the selling stockholder is deemed an underwriter under the Securities Act. The prospectus sections also note that investing in CirTran common stock involves a high degree of risk and direct readers to detailed risk factor discussions.
Users can also review CirTran’s Current Report on Form 8-K describing entry into the Standby Equity Purchase Agreement and a related forbearance arrangement with Tekfine, LLC. This 8-K outlines how advances under the equity facility are priced by reference to the volume-weighted average price of CirTran’s common stock, how the company controls the timing and size of any advances, and how a portion of proceeds is required to be applied to debt reduction.
In addition, CirTran’s Form 12b-25 (NT 10-Q) filing explains a delay in submitting its Form 10-Q for the period ended September 30, 2025, citing the need for additional time to compile documentation and complete the review process. Through Stock Titan, investors can use AI-powered summaries to interpret these filings, understand the implications of CirTran’s equity financing structure, track its reporting status as a smaller reporting company, and follow changes disclosed across its registration statements, current reports, and periodic filings.
CirTran Corporation is registering up to 1,731,509 shares of common stock for resale tied to a $10,000,000 standby equity purchase agreement. The shares may be issued over 24 months to YA II PN, Ltd. at 95% of the lowest volume-weighted average price over a three‑day period, subject to a 4.99% ownership cap. Common stock outstanding is 4,945,417 shares before this arrangement and would be 6,676,926 shares if all registered shares are issued.
CirTran will not receive proceeds from the resale itself but may raise up to $10,000,000 from primary sales to the investor, with 50% of any cash required to repay secured debt owed to Tekfine, LLC. The company reports continued net losses, an accumulated deficit of about $62.8 million, and a working capital deficit of roughly $22.9 million, and its auditors have issued a going concern warning. Management discloses potential insolvency, approximately $4.4 million of secured convertible debentures and interest that encumber all assets, and highlights that this equity line and any additional equity financings could cause substantial dilution and pressure on its low-priced OTC-traded shares.
CirTran Corporation has filed an S-1 registering up to 1,731,509 shares of common stock for resale by YA II PN, Ltd. under a standby equity purchase agreement of up to
The registered shares equal about 40% of the float and could materially dilute existing holders, on top of penny stock trading on the OTCID at
CirTran reports continued losses, with
CirTran Corporation entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. that gives the company the right, but not the obligation, to sell up to $10,000,000 of its common stock to YA over a 24‑month period. CirTran will decide when and how many shares to sell through individual advances, with pricing based on the stock’s volume weighted average price, and the company may set a minimum acceptable price for certain advances.
CirTran plans to file a registration statement to cover YA’s resale of any shares it may buy and is required to issue 3,846,154 shares of common stock to YA in December 2026. The agreement caps YA’s beneficial ownership at 4.99% of CirTran’s outstanding common stock at any time. The company expects to use proceeds for working capital and general corporate purposes and must apply 50% of any proceeds to reduce indebtedness, including accrued interest, owed to Tekfine, LLC, which has agreed to refrain from selling stock received on note conversions during the agreement’s term. Both YA and Tekfine have agreed not to engage in short sales or net short positions in CirTran’s stock during the term.
CirTran Corporation (CIRX) reported another quarterly loss and remains financially distressed. For the three months ended September 30, 2025, net sales rose to $448,492 from $256,070, mainly from stronger vapor product sales, lifting gross profit to $177,826. For the nine months, revenue was broadly flat at $1,077,743, while gross profit fell to $533,062 as costs increased.
The nine‑month net loss narrowed to $1,138,064 from $1,814,150, helped by lower derivative valuation losses, but interest expense of $612,219 and a derivative loss of $34,552 still weighed on results. Cash from operations was negative $1,031,790 and was covered largely by related‑party loans of $1,051,064.
At September 30, 2025, total assets were $1.9 million against liabilities of $27.5 million, including a working capital deficit of about $22.9 million, accumulated deficit of $62.8 million, and derivative liabilities of $2.49 million. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern, and disclosure controls and procedures were deemed not effective.
CirTran Corporation (CIRX) filed a Form 12b-25 (NT 10-Q), notifying a delay in its Quarterly Report for the period ended September 30, 2025. The company states it needs additional time to compile and analyze supporting documentation and to allow its independent registered public accounting firm to complete its review of the financial statements. CirTran indicates it intends to file the Form 10-Q as soon as possible.